What's the Most Weight Loss People Actually See on Wegovy?

The myth: everyone on Wegovy loses 15% of their body weight

The 15% figure from the STEP 1 trial is widely repeated, and it's legitimate, but it's an average across roughly 1,300 participants, not a minimum or a target. Averages are pulled upward by people who responded exceptionally well and downward by those who didn't respond much at all. In STEP 1, published in the New England Journal of Medicine, participants on 2.4mg semaglutide lost an average of around 14.9% of body weight versus about 2.4% on placebo over 68 weeks. That's a genuine and meaningful difference. But roughly a third of participants lost less than 10%, and a roughly equivalent proportion lost more than 20%. If you go in expecting 15% as a given, you may be either disappointed or pleasantly surprised, depending on where you happen to fall. Genetics, baseline weight, adherence to lifestyle changes, and how well you tolerate the escalation schedule all push results up or down. For a fuller picture of what weight loss on Wegovy looks like across different starting points, the real-world data is worth reading alongside the trial figures.

Where the highest results actually come from

The most weight loss reported in a Wegovy trial (around 20.7% average reduction) comes from the higher-dose 7.2mg programme. The MHRA approved the dedicated single-dose 7.2mg pen on 14 April 2026, initially following a 2.4mg weekly injection pathway before the single pen became available. That approval is for adults with BMI 30 or above; it doesn't apply to the cardiovascular indication or to people with a lower BMI. The titration still starts at 0.25mg and climbs gradually, so reaching 7.2mg maintenance takes considerable time. Even at that dose, 20.7% is still an average: some participants in the higher-dose programme lost substantially more, and others less. Separately, in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4mg, worth knowing if you're weighing up options, though which medicine suits you is a question for your prescriber rather than a league table. A full overview of Wegovy's evidence, doses and UK licensing covers this in more depth.

What actually affects how much you lose

The trial populations were adults with obesity or overweight and at least one weight-related condition, following a reduced-calorie diet and increased physical activity alongside treatment. That context matters. Semaglutide reduces appetite and slows gastric emptying, which makes eating less feel more manageable rather than a matter of willpower, but the calorie deficit still has to be there. People who pair treatment with genuinely sustainable dietary changes and regular movement tend to sit in the upper half of the results distribution. Dose escalation also plays a role: most people titrate through 0.25mg, 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg maintenance. What happens in the first week is quite different from what happens at month six. If you're not seeing the results you expected mid-treatment, there are practical steps worth discussing with your prescriber, our page on how to support weight loss on Wegovy sets those out clearly. The NHS notes that if less than 5% weight loss has occurred after six months on the maintenance dose, continuing should be reviewed. That's a clinical checkpoint, not a verdict. How long Wegovy takes to show results varies by person, and the early weeks are rarely the most representative.

If results plateau or stall

A weight-loss plateau during Wegovy treatment is common and doesn't necessarily mean the medicine has stopped working. After 60–68 weeks, the rate of loss typically slows as the body adjusts. Many people find their weight stabilises at a lower point rather than continuing to fall. Stopping treatment at that stage often leads to gradual weight regain, which is why ongoing clinical review matters. There's also the question of whether you're on the right dose for you, or whether additional support around diet, sleep and activity would shift things. If you're seeing no weight loss at all on Wegovy, that's a different situation and worth exploring separately, several clinical and practical explanations exist. Pricing context is relevant for people managing long-term treatment; the cost of ongoing supply is covered on our guide to where to buy Wegovy in the UK. If you'd like to discuss your results or options with a prescriber, check your eligibility through a free consultation with our clinical team.